

ORDER ID
For Invitae internal use only

Requisition Form
BEHIND THE SEIZURE TRF952-1

This requisition form can be used to submit a specimen for the Behind The Seizure® program, a complimentary Invitae Epilepsy Panel Canada testing program brought to you by BioMarin Pharmaceutical Inc., Stoke Therapeutics, Xenon Pharmaceuticals, and Invitae Corporation. Please confirm that the patient meets the eligibility requirements for the program. To submit orders for genetic testing outside of this program, please order through Invitae's online portal or use a standard requisition form, accessible at <a href="https://www.invitae.com/order-forms">www.invitae.com/order-forms</a>.

## PROGRAM ELIGIBILITY:

Any child up to 60 months old who has had an unprovoked seizure.

PATIENT INFORMATIO		3116113	ora wire mas m		ORGANIZATION		ATION				
	N					INFORM	ATION				
This thank	Last name			Organization name and address							
Date of birth (MM/DD/YYYY) Biological sex MRN (medical re	MRN (medical record number)				Organization name						
Ancestry Asian Black/African American White/Cau				Phone			Fax				
Hispanic Native American Pacific Islander French Canadian Sephardic Jewish Mediterranean Other:				Address			City				
Phone Email address			Province		Postal code	Country					
Address	City		Primary	clinical con	tact						
Province Postal code Country			Name				Role/title				
SPECIMEN INFORMATION	)N		Phone		Email address (for repo	rt access)					
Label each tube with the patient's full name, date of birth, and spe A requisition form MUST accompany each specimen. www.invitae				g physician							
Specimen type : O Blood O Saliva O Assisted saliva O DN	A - source:		O Sam	e as primary c	linical contact						
DNA must be extracted in a CLIA or other suitably certified laborator We are unable to accept blood/saliva from patients with:			Name	Name			Role/title				
Allogeneic bone marrow transplants  • Blood transfusion <2 weeks prior to specimen collection  Collection date (MM/DD/YYYY)  If not provided, date will be 1 day prior to our receipt of											
specimen. For DNA, provide		Additional clinical or laboratory contact (optional)									
Special cases: O History of/current hematologic malignancy	Name	Name Email address (for report access)									
REASON FOR TESTING	;										
Previous results (if applicable and not included in clinical criteria	enclose copy	of report)	INV	ITAE PAF	RTNER CODE	BTS					
					FAMILY VARI	ANT TESTI	NG				
BEHIND THE SEIZURE PROGRAM ELIGIE INFORMATION	ILITY/C	LINIC	AL the orig	inal family n	ant testing programs nember's variant was amily-testing.						
Required patient information:			Please at	tach the proba	nd's clinical report or prov	ide Invitae RQ#					
Current age of child (in months): months (For eligibility, the patient must be <60 months old)			INVITAE PR	OBAND RQ#	RELATIONSHIP TO PROBAND	GENE(S)	VAR	IANT(S)			
Age of child (in months) at onset of unprovoked seizures:	n	nonths									
Required medical history:			Required	d medical his	story (continued):						
Generalized seizures (check all that apply)	Υ				s if available		Υ	N	Unknown		
Febrile seizures					ults at the end of this fo						
Generalized seizures					e, panel, exome, or CN	1A)					
Focal seizures					ing metabolic)						
Other			Abnorm								
			Abnorm Previous		71) enzyme testing						
Family history of epilepsy				2 02:12 (	, , , , , , , , , , ,						
Family history of epilepsy  Developmental delays			Suspicio	on of genetic	basis of epilepsy						
Developmental delays Language development delay			Suspicio	on of genetic		ic syndrome or	disorder. P	lease	specify:		
Developmental delays			Suspicio	on of genetic	basis of epilepsy	ic syndrome or	disorder. P	lease	specify:		

Y = test performed and/or medical history taken AND material finding reported; N = test performed and/or medical history taken AND no material finding; Unknown = not in medical record and/or test not performed



#### **RE-REQUISITION**

Invitae offers one re-requisition at no additional charge within 90 days for genes related to the original clinical area. For more information and to request online, please visit www.invitae.com/re-requisition.

#### PRELIMINARY-EVIDENCE GENES

Invitae's primary panels contain genes for which there is definitive evidence that variants in these genes cause specific diseases. Preliminary-evidence genes are genes for which there is only early evidence of a relationship between variants in these genes and specific diseases. All preliminary-evidence genes are indicated as such on the requisition form below.

#### **ASSAY**

Invitae is a CAP-accredited and CLIA-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS). Search for details on the analysis of any gene in our test catalog at <a href="https://www.invitae.com/physician/search">www.invitae.com/physician/search</a>.

To request a complimentary specimen collection kit visit www.invitae.com/request-a-kit

### SHIPPING INSTRUCTIONS

Please ship specimen to Invitae:

Attn: Invitae Client Services 1400 16th Street San Francisco, CA 94103 USA

Invitae continually updates its panels based on the most recent evidence. Please note that if an order is placed using an older version of this form, Invitae reserves the right to upgrade any ordered panel (s) to the current version(s).

# TESTS INCLUDED IN THE PROGRAM

INVITAE EPILEPSY PANEL								
Test code	Test name		# of genes	Gene list				
O3401 Invitae Epilepsy Panel		146	ADSL, ALDH5A1, ALDH7A1, ALG13, ARHGEF9, ARX, ATP1A2, ATP1A3, ATRX, BRAT1, C12orf57, CACNA1A, CACNA2D2, CARS2, CASK, CDKL5, CHD2, CHRNA2, CHRNA4, CHRNB2, CLCN4, CLN2 (TPP1), CLN3, CLN5, CLN6, CLN8, CNTNAP2, CSTB, CTSD, DEPDC5, DNAJC5, DNM1, DOCK7, DYRK1A, EEF1A2, EFHC1, EHMT1, EPM2A, FARS2, FOLR1, FOXG1, FRRS1L, GABBR2, GABRA1, GABRB2, GABRB3, GABRG2, GAMT, GATM, GLRA1, GNAO1, GOSR2, GRIN1, GRIN2A, GRIN2B, HCN1, HNRNPU, IER3IP1, IQSEC2, ITPA, JMJD1C, KANSL1, KCNA2, KCNB1, KCNC1, KCNH2, KCNJ10, KCNMA1, KCNQ2, KCNQ3, KCNT1, KCTD7, LGI1, LIAS, MBD5, MECP2, MEF2C, MFSD8, MTOR, NEDD4L, NEXMIF, NGLY1, NHLRC1, NPRL3, NRXN1, PACS1, PCDH19, PIGA, PIGN, PIGO, PLCB1, PNKD, PNKP, PNPO, POLG, PPT1, PRICKLE1, PRIMA1, PRRT2, PURA, QARS, RELN, ROGDI, SATB2, SCARB2, SCN1A, SCN1B, SCN2A, SCN3A, SCN8A, SCN9A, SERPINI1, SGCE, SIK1, SLC12A5, SLC13A5, SLC19A3, SLC25A12, SLC25A22, SLC2A1, SLC35A2, SLC6A1, SLC6A8, SLC9A6, SMC1A, SNX27, SPATA5, SPTAN1, ST3GAL5, STRADA, STX1B, STXBP1, SYN1, SYNGAP1, SYNJ1, SZT2, TBC1D24,TCF4, TPK1, TSC1, TSC2, UBE3A, WDR45, WWOX, ZDHHC9, ZEB2					
	O 03401.1  Fill in the circle to add these genes to your order	Add-on preliminary-evidence genes	35	ABAT, ARHGEF15, ATP6AP2, CACNA1H, CACNB4, CASR, CERS1, CNTN2, CPA6, DIAPH1, FASN, GABRD, GAL, GPHN, KCNA1, KCND2, KCNH5, KPNA7, LMNB2, NECAP1, PIGG, PIGQ, PIK3AP1, PRDM8, PRICKLE2, RBFOX1, RBFOX3, RYR3, SCN5A, SETD2, SLC35A3, SNAP25, SRPX2, ST3GAL3, TBL1XR1				
	03401.2	Add-on genes for glycine encephalopathy	3	AMT, GCSH, GLDC				
	03401.3	Add-on FLNA gene	1	FLNA				
	03401.4	Add-on PTEN gene	1	PTEN				
	03401.5	Add-on RANBP2 gene	1	RANBP2				

By signing this form, the medical professional acknowledges that the individual/family member authorized to make decisions for the individual (collectively, the "Patient") has been supplied information regarding and consented to undergo genetic testing, substantially as set forth in Invitae's Informed Consent for Genetic Testing (www.invitae.com/patient-consent). And in connection with the Behind the Seizure program, the Patient has been informed that Invitae may notify them of clinical updates related to genetic test results (in consultation with the ordering medical professional as indicated) and has been informed that Invitae may share clinician and institution contact information and certain Patient de-identified information (age, gene, variant, and classification) but not including the name of Patient or Patient's guardian, with third parties, including BioMarin Pharmaceuticals, Inc., Stoke Therapeutics, and Xenon Pharmaceuticals, for research and commercial purposes and to contact their medical professional. The Patient has been informed that (i) the Patient's personal information and specimen will be transferred from Canada to the U.S. for processing in the U.S. and (ii) de-identified Patient data may be used and shared for research and commercial purposes in the U.S. The medical professional warrants that he/she will not seek reimbursement for this sponsored test from any third party, including but not limited to government healthcare programs. The medical professional also hereby acknowledges that organization and clinician contact information provided in the order may be shared with third parties, including BioMarin Pharmaceuticals, Inc., Stoke Therapeutics, and Xenon Pharmaceuticals that may contact the medical professional directly in connection with the Behind the Seizure program, or their products. The medical professional understands that the use of this sponsored test is not intended to be, nor should it be construed as, either express or implied, an obligation or inducement for the medical prof

